Chai Kern Y, Byrne Anna L, Morison Ian M
Department of Pathology, University of Otago, Hercus Building, 56 Hanover St, Dunedin, 9016, New Zealand.
Southern Blood & Cancer Service, Dunedin Hospital, 201 Great King St, Dunedin, 9016, New Zealand.
J Med Case Rep. 2018 May 10;12(1):124. doi: 10.1186/s13256-018-1636-9.
Clarithromycin is an efficacious treatment for myeloma in combination with other anti-myeloma therapy but not as monotherapy. To date, all studies have focused on a clarithromycin-specific effect rather than a class effect (macrolide) and there is no information on the activity of roxithromycin in myeloma.
Here we report an untreated 86-year-old New Zealand European white man with IgA myeloma whose paraprotein decreased by 57%, consistent with a partial response, after a course of roxithromycin for pneumonia. His paraprotein reduced from 46 to 20 g/L while his hemoglobin improved from 97 to 123 g/L after 1 month.
Additional investigations should be considered to elucidate the therapeutic effect of roxithromycin in myeloma.
克拉霉素与其他抗骨髓瘤疗法联合使用时对骨髓瘤有效，但不能作为单一疗法。迄今为止，所有研究都集中在克拉霉素的特异性作用而非类效应（大环内酯类），且尚无关于罗红霉素在骨髓瘤中活性的信息。
我们在此报告一名未接受过治疗的86岁新西兰欧洲裔白人男性，患有IgA骨髓瘤，在接受一个疗程的罗红霉素治疗肺炎后，其副蛋白下降了57%，符合部分缓解。1个月后，他的副蛋白从46克/升降至20克/升，同时血红蛋白从97克/升升至123克/升。
应考虑进一步研究以阐明罗红霉素在骨髓瘤中的治疗效果。
